BORDERLINE PANCREATIC FUNCTION IN CYSTIC FIBROSIS

该项目的长期目标是开发一种非侵入性方法，用于准确测量囊性纤维化(CF)患者和其他影响胰腺外分泌功能的疾病的交界性外分泌功能不全。我们的方法是同时给予13C标记的甘油三酯(13C-TG)、不可吸收的标记物DyCl3和粪便视觉标记物FD&C Blue#1(亮蓝，BB)和脂肪餐，然后收集和分析单个粪便样本中的13C-过量和Dy。这两种测量方法可以准确地确定患者排出的13C-TG的量，而不需要几天的粪便定量收集。在拟议项目的第一阶段，我们将测试13C-TG的胰腺水解度受甘油三酯中饱和脂肪酸链长的强烈影响的假设。在第二阶段的研究中，我们将测试一些具有修饰脂肪酸特性的13C-TGS，以确定TG结构对结果方法评估交界性外分泌功能不全的敏感性的影响。建议的商业应用：这项研究将导致一种评估临界胰腺功能的非侵入性测试。它在评估胰腺充足但有胰腺衰竭风险的囊性纤维化患者中有应用价值。

The long-term objectives of this proposed project are to develop a noninvasive procedure for accurate measurement of borderline exocrine pancreatic insufficiency in cystic fibrosis (CF) patients and other disorders affecting exocrine pancreatic function. Our approach is based on simultaneous administration of a 13C-labeled triglyceride (13C-TG), the nonabsorbable marker DyCl3, and the visual fecal marker FD&C Blue #1 (Brilliant Blue, "BB") with a fatty meal followed by collection and analysis of a single sample of stool for 13C-Excess and Dy. These two measurements permit accurate determination of the amount of 13C-TG excreted by the patient without the need for quantitative collection of stools for several days. During Phase-I of the proposed project, we will test the hypothesis that the sensitivity of pancreatic hydrolysis of 13C-TG is strongly influenced by the chain-length of the saturated fatty acids present in the TG. During Phase-II research, we will test a number of 13C-TGs with modified fatty acid characteristics in order to define the effect of TG structure on the sensitivity of the resultant method for specific application to evaluation of borderline exocrine pancreatic insufficiency. PROPOSED COMMERCIAL APPLICATIONS: This research will lead to a noninvasive test for assessment of borderline pancreatic function. It has applications in evaluating cystic fibrosis patients who are pancreatic sufficient but at risk of pancreatic failure.